Updated:
Harvard Bioscience
Harvard Bioscience provides life sciences equipment and instruments to academic research institutions, pharmaceutical and biotech companies, and contract...
Harvard Bioscience
Harvard Bioscience provides life sciences equipment and instruments to academic research institutions, pharmaceutical and biotech companies, and contract research organizations. It supports preclinical research from cellular and molecular work through toxicology and bioprocessing. Its products are designed and manufactured in the US and Europe, with a history of over 120 years.
General information
Firm type
Public Company
Location
Region
North America
Country
United States
City
Holliston
Corporate office
Holliston, MA, United States
Principals
John Duke
Chief Executive Officer
Mark Frost
Chief Financial Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Harvard Bioscience?
Harvard Bioscience is a public company, not a family office. Investment decisions regarding capital allocation and operational strategy are made by CEO John Duke and CFO Mark Frost, subject to oversight by its board of directors (per firm website, 2026).
What is Harvard Bioscience's known posture on co-investments alongside external GPs?
Harvard Bioscience does not participate in co-investments as a family office or fund. Its capital deployment is limited to internal business operations, such as the ongoing consolidation of manufacturing facilities.
How does Harvard Bioscience source proprietary deal flow?
As a publicly traded life-sciences equipment company, Harvard Bioscience does not source investment deal flow. It develops and sells lab instruments through direct sales and distribution channels to academic, CRO, and pharma customers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: